William Blair on Sarepta Therapeutics (SRPT): 'we continue to view the stock’s near-term upside potential as limited'
Tweet Send to a Friend
William Blair analyst Sami Corwin reiterated a Market Perform rating on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments "Stock thoughts ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
